Non-alcoholic fatty liver disease (NAFLD) is a major national and international health burden. It is one of the most common liver diseases worldwide and the most common cause of abnormal liver enzymes in many developed countries. Non-alcoholic fatty liver disease is also known as an important cause of cryptogenic cirrhosis and second leading cause for liver transplantation. It is commonly associated with metabolic syndrome. Non-alcoholic steatohepatitis (NASH) is the progressive phenotype of NAFLD. In spite of promising performance of non-invasive tools, liver biopsy remains the gold standard test for NASH diagnosis. Over decades, many drugs have been investigated in phase 2 and 3; however, no approved therapy to date. Despite the alarming global rates of NAFLD, there are no local community-based studies on the prevalence of NAFLD or local practice guidelines on its management; this expert review aims to fill this gap.
CITATION STYLE
Alswat, K. A., Fallatah, H. I., Al-Judaibi, B., Elsiesy, H. A., Al-Hamoudi, W. K., Qutub, A. N., … Al-Osaimi, A. (2019). Position statement on the diagnosis and management of non-alcoholic fatty liver disease. Saudi Medical Journal, 40(6), 531–540. https://doi.org/10.15537/smj.2019.6.23980
Mendeley helps you to discover research relevant for your work.